Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study

Prognosis is poor for patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) after failure of or who are ineligible for autologous stem cell transplant. We evaluated the efficacy and safety of tislelizumab, an investigational anti-PD-1 monoclonal antibody, in phase 2, single-arm st...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yuqin, Gao, Quanli, Zhang, Huilai, Fan, Lei, Zhou, Jianfeng, Zou, Dehui, Li, Wei, Yang, Haiyan, Liu, Ting, Wang, Quanshun, Lv, Fangfang, Guo, Haiyi, Yang, Liudi, Elstrom, Rebecca, Huang, Jane, Novotny, William, Wei, Vivian, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214259/
https://www.ncbi.nlm.nih.gov/pubmed/31520078
http://dx.doi.org/10.1038/s41375-019-0545-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214259/
https://www.ncbi.nlm.nih.gov/pubmed/31520078
http://dx.doi.org/10.1038/s41375-019-0545-2

Ejemplares similares